Global Peptide Therapeutics Market 2016-2020 - Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com with Peptide Therapeutics Market in subject line and your contact details. Read 81Pages Report at http://www.reportsnreports.com/reports/509010-global-peptidetherapeutics-market-2016-2020.html . Peptides are organic compounds that are composed of amino acids linked chemically by peptide bonds. They are the most potent biologically active substances found in nature and are used to trigger, control, and maintain an individual's physiological processes. However, using peptides as therapeutic agents was always difficult as they are quite instable and cannot pass through cellular membranes. They also require a specific technology to tackle extensive and challenging steps in their synthesis. Over 80 peptides are marketed by companies that explore the probabilities of designing and engineering peptides that can overcome their natural limits. They can be introduced as a treatment for chronic indications. The analysts forecast global peptide therapeutics market to grow at a CAGR of 7.92% during the period 2016-2020. Covered in this report This report covers the present scenario and the growth prospects of the global peptide therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of prescription and generic drugs used to treat diseases. The market is divided into the following segments based on geography:   
Americas APAC EMEA
The report, Global Peptide Therapeutics Market 2016-2020, has been prepared based on an indepth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Buy a copy of report @ http://www.reportsnreports.com/Purchase.aspx?name=509010 for US $2500. Key vendors
Global Peptide Therapeutics Market 2016-2020
Eli Lilly Novo Nordisk Sanofi Takeda Pharmaceutical Teva Pharmaceuticals
Other prominent vendors
AbbVie Advanced Accelerator Applications Akashi Therapeutics Amgen Anthera Pharmaceuticals AstraZeneca Bachem Bristol-Myers Squibb Cardiorentis Corden Pharma International Debiopharm Derma Sciences GlaxoSmithKline Hanmi Pharmaceutical Insmed Ipsen Johnson & Johnson Lonza Mallinckrodt MolMed Merck Novartis Nymox Pharmaceutical Par Pharmaceuticals PeptiDream Polypeptide Group Radius Health Repligen Roche SciClone Shire The Medicines Company Transition Therapeutics X-Gen Pharmaceuticals
Global Peptide Therapeutics Market 2016-2020
Zealand Pharma Zydus Cadila
Inquire before Buying at http://www.reportsnreports.com/contacts/InquiryBeforeBuy.aspx?name=509010 . Market driver
Increase in patient population
Market challenge
High cost of therapy
Market trend
Shifting focus toward untapped markets
Key questions answered in this report 1. 2. 3. 4. 5. 6. 7.
What will the market size be in 2020 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors?
Inquire for Discount at http://www.reportsnreports.com/contacts/Discount.aspx?name=509010 . List of Exhibits Exhibit 01: Product offerings Exhibit 02: SWOT analysis: Peptide therapeutics Exhibit 03: Steps involved in peptide synthesis Exhibit 04: Optimization of peptide synthesis Exhibit 05: Methods used to stabilize peptides Exhibit 06: Global peptide therapeutics market 2015-2020 ($ billions) Global Peptide Therapeutics Market 2016-2020
Exhibit 07: Five forces analysis Exhibit 08: Global peptide therapeutics market segmentation based on route of administration Exhibit 09: Global peptide therapeutics market segmentation by route of administration 2015 Exhibit 10: Global peptide therapeutics market segmentation by drug class Exhibit 11: Global peptide therapeutics market segmentation by synthesis technology Exhibit 12: Global peptide therapeutics market segmentation by geography 2015 Exhibit 13: Peptide therapeutics market revenue by geography 2015-2020 ($ billions) Exhibit 14: Peptide therapeutics market in Americas 2015-2020 ($ billions) Exhibit 15: Peptide therapeutics market in EMEA 2015-2020 ($ billions) Exhibit 16: Peptide therapeutics market in APAC 2015-2020 ($ billions) Exhibit 17: Global peptide therapeutics market: YoY growth and revenue based on geography 2015-2020 Exhibit 18: Impact of drivers Exhibit 19: Impact of drivers and challenges Exhibit 20: El Lilly: YoY growth rate and revenue of Humalog 2012-2014 ($ billions) Exhibit 21: Eli Lilly: YoY growth rate and revenue of Cialis 2012-2014 ($ billions) Exhibit 22: Eli Lilly: YoY growth rate and revenue of Cymbalta 2012-2014 ($ billions) Exhibit 23: Eli Lilly: YoY growth rate and revenue of Humulin 2012-2014 ($ billions) Exhibit 24: Eli Lilly: YoY growth rate and revenue of Forteo 2012-2014 ($ billions) Exhibit 25: Eli Lilly: Key takeaways Exhibit 26: Novo Nordisk: YoY growth rate and revenue of NovoLog/NovoRapid 2012-2014 ($ billions) Exhibit 27: Novo Nordisk: Geographical split of revenues of NovoLog 2014
Global Peptide Therapeutics Market 2016-2020
Exhibit 28: Novo Nordisk: YoY growth rate and revenue of NovoMix/NovoLog mix 2012-2014 ($ billions) Exhibit 29: Novo Nordisk: Geographical split of revenues of NovoMix 2014 Exhibit 30: Novo Nordisk: YoY growth rate and revenue of Norditropin 2012-2014 ($ billions) Exhibit 31: Novo Nordisk: Geographical split of revenues of Norditropin 2014 Exhibit 32: Novo Nordisk: YoY growth rate and revenue of Prandin 2012-2014 ($ millions) Exhibit 33: Novo Nordisk: Geographical split of revenues of Prandin 2014 Exhibit 34: Novo Nordisk: Key takeaways Exhibit 35: Sanofi: YoY growth rates and revenues of Lantus 2012-2014 ($ billions) Exhibit 36: Sanofi: YoY growth rate and revenue of Amaryl 2012-2014 ($ millions) Exhibit 37: Sanofi: YoY growth rate and revenue of Apidra 2012-2014 ($ millions) Exhibit 38: Sanofi: YoY growth rate and of Insuman 2012-2014 ($ millions) Exhibit 39: Sanofi: YoY revenue of Lyxumia 2013-2014 ($ millions) Exhibit 40: Sanofi: Key takeaways Exhibit 41: Takeda Pharmaceutical: YoY revenue of Velcade 2013-2014 ($ billions) Exhibit 42: Takeda Pharmaceutical: YoY revenue of Leuprorelin 2013-2014 ($ billions) Exhibit 43: Takeda Pharmaceutical: YoY revenue of Nesina 2013-2014 ($ millions) Exhibit 44: Takeda Pharmaceutical: YoY revenue of TachoSil 2013-2014 ($ millions) Exhibit 45: Takeda Pharmaceutical: Key takeaways Exhibit 46: Teva Pharmaceuticals: YoY growth rate and revenue of Copaxone 2012-2014 ($ billions) Exhibit 47: Teva Pharmaceuticals: Key takeaways Browse All Reports on Pharmaceuticals
Global Peptide Therapeutics Market 2016-2020
About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.
Global Peptide Therapeutics Market 2016-2020